Department of Anesthesia and Intensive Care, Ospedale S. Antonio, Via Facciolati, 71, Padova, Italy.
BMC Anesthesiol. 2019 May 1;19(1):62. doi: 10.1186/s12871-019-0733-7.
Acute kidney injury (AKI) is strongly associated with high morbidity and mortality of critically ill patients. In the last years several different biological markers with higher sensitivity and specificity for the occurrence of renal impairment have been developed in order to promptly recognize and treat AKI. Nonetheless, their potential role in improving patients' outcome remains unclear since the effectiveness of an "earlier" initiation of renal replacement therapy (RRT) is still debated. Since one large, high-quality randomized clinical trial has been recently pubblished, we decided to perform a meta-analysis of all the RCTs ever performed on "earlier" initiation of RRT versus standard RRT in critically ill patients with AKI to evaluate its effect on major outcomes.
Pertinent studies were independently searched in BioMedCentral, PubMed, Embase, and Cochrane Central Register of clinical trials. The following inclusion criteria were used: random allocation to treatment ("earlier" initiation of RRT versus later/standard initiation); critically ill patients.
Ten trials randomizing 2214 patients, 1073 to earlier initiation of RRT and 1141 to later initiation were included. No difference in mortality (43.3% (465 of 1073) for those receiving early RRT and 40.8% (466 of 1141) for controls, p = 0.97) and survival without dependence on RRT (3.6% (34 of 931) for those receiving early RRT and 4.2% (40 of 939) for controls, p = 0.51) were observed in the overall population. On the contrary, early initiation of RRT was associated with a significant reduction in hospital length of stay. No differences in occurrence of adverse events were observed.
Our study suggests that early initiation of RRT in critically ill patients with AKI does not provide a clinically relevant advantage when compared with standard/late initiation.
急性肾损伤(AKI)与危重病患者的高发病率和死亡率密切相关。在过去的几年中,为了及时发现和治疗 AKI,已经开发出了几种具有更高敏感性和特异性的不同生物标志物。然而,它们在改善患者预后方面的潜在作用仍不清楚,因为更早开始肾脏替代治疗(RRT)的效果仍存在争议。由于最近发表了一项大型、高质量的随机临床试验,我们决定对所有关于 AKI 危重病患者更早开始 RRT 与标准 RRT 的 RCT 进行荟萃分析,以评估其对主要结局的影响。
在 BioMedCentral、PubMed、Embase 和 Cochrane 临床试验中心注册库中独立搜索相关研究。使用以下纳入标准:随机分配至治疗(更早开始 RRT 与更晚/标准开始);危重病患者。
纳入了 10 项随机分配 2214 名患者的试验,1073 名患者接受更早开始 RRT,1141 名患者接受更晚开始 RRT。两组死亡率无差异(接受早期 RRT 的患者为 43.3%(465/1073),对照组为 40.8%(466/1141),p=0.97),且无需依赖 RRT 生存的比例也无差异(接受早期 RRT 的患者为 3.6%(34/931),对照组为 4.2%(40/939),p=0.51)。然而,更早开始 RRT 与住院时间的显著缩短相关。两组不良事件的发生率无差异。
本研究表明,与标准/晚期开始相比,AKI 危重病患者更早开始 RRT 并不能提供临床相关优势。